Literature DB >> 29158589

Lung cancer in 2017: Giant steps and stumbling blocks.

David F Heigener1, Martin Reck1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29158589     DOI： 10.1038/nrclinonc.2017.178

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Authors:  David P Carbone; Martin Reck; Luis Paz-Ares; Benjamin Creelan; Leora Horn; Martin Steins; Enriqueta Felip; Michel M van den Heuvel; Tudor-Eliade Ciuleanu; Firas Badin; Neal Ready; T Jeroen N Hiltermann; Suresh Nair; Rosalyn Juergens; Solange Peters; Elisa Minenza; John M Wrangle; Delvys Rodriguez-Abreu; Hossein Borghaei; George R Blumenschein; Liza C Villaruz; Libor Havel; Jana Krejci; Jesus Corral Jaime; Han Chang; William J Geese; Prabhu Bhagavatheeswaran; Allen C Chen; Mark A Socinski
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

Review 2.  Crizotinib.

Authors:  David F Heigener; Martin Reck
Journal:  Recent Results Cancer Res       Date:  2014

3.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Authors:  Toyoaki Hida; Hiroshi Nokihara; Masashi Kondo; Young Hak Kim; Koichi Azuma; Takashi Seto; Yuichi Takiguchi; Makoto Nishio; Hiroshige Yoshioka; Fumio Imamura; Katsuyuki Hotta; Satoshi Watanabe; Koichi Goto; Miyako Satouchi; Toshiyuki Kozuki; Takehito Shukuya; Kazuhiko Nakagawa; Tetsuya Mitsudomi; Nobuyuki Yamamoto; Takashi Asakawa; Ryoichi Asabe; Tomohiro Tanaka; Tomohide Tamura
Journal:  Lancet       Date:  2017-05-10       Impact factor: 79.321

Review 4.  Refining the treatment of NSCLC according to histological and molecular subtypes.

Authors:  Anish Thomas; Stephen V Liu; Deepa S Subramaniam; Giuseppe Giaccone
Journal:  Nat Rev Clin Oncol       Date:  2015-05-12       Impact factor: 66.675

5.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

8.  Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.

Authors:  Seng Chuan Tang; Luan N Nguyen; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Journal:  Int J Cancer       Date:  2013-10-03       Impact factor: 7.396

9.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245
  9 in total
  12 in total

1.  Caspase-8 knockdown suppresses apoptosis, while induces autophagy and chemo-sensitivity in non-small cell lung cancer cells.

Authors:  Hui Zuo; Cheng Chen; Ling Ma; Qiu-Xia Min; Yue-Hai Shen
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  Circular RNA circ-SLC7A6 acts as a tumor suppressor in non-small cell lung cancer through abundantly sponging miR-21.

Authors:  Yuan Wang; Fushuang Zheng; Zibo Wang; Jibin Lu; Hongyan Zhang
Journal:  Cell Cycle       Date:  2020-08-14       Impact factor: 4.534

3.  ACT001 inhibits the proliferation of non-small cell lung cancer cells by upregulating NKTR expression.

Authors:  Min Zhao; Tingting Qin; Dingzhi Huang
Journal:  Thorac Cancer       Date:  2022-05-10       Impact factor: 3.223

4.  Pathological Mechanistic Studies of Osimertinib Resistance in Non-Small-Cell Lung Cancer Cells Using an Integrative Metabolomics-Proteomics Analysis.

Authors:  Qing Ma; Jing Wang; Yaoyao Ren; Fanlu Meng; Lili Zeng
Journal:  J Oncol       Date:  2020-03-17       Impact factor: 4.375

5.  Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer.

Authors:  Yang Zheng; Lili Tang; Ziling Liu
Journal:  BMC Cancer       Date:  2021-12-10       Impact factor: 4.430

6.  lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling.

Authors:  Jinchang Pan; Shuai Fang; Haihua Tian; Chengwei Zhou; Xiaodong Zhao; Hui Tian; Jinxian He; Weiyu Shen; Xiaodan Meng; Xiaofeng Jin; Zhaohui Gong
Journal:  Mol Cancer       Date:  2020-01-15       Impact factor: 27.401

7.  5-HT7 Receptor Contributes to Proliferation, Migration and Invasion in NSCLC Cells.

Authors:  Xiaohui Du; Ting Wang; Zhihua Wang; Xiaomei Wu; Yiya Gu; Qian Huang; Jianmiao Wang; Jungang Xie
Journal:  Onco Targets Ther       Date:  2020-03-09       Impact factor: 4.147

8.  Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer.

Authors:  Wei-Ran Liu; Bin Zhang; Chen Chen; Yue Li; Xin Ye; Dong-Jiang Tang; Jun-Cheng Zhang; Jing Ma; Yan-Ling Zhou; Xian-Jun Fan; Dong-Sheng Yue; Chen-Guang Li; Hua Zhang; Yu-Chen Ma; Yan-Song Huo; Zhen-Fa Zhang; Shu-Yu He; Chang-Li Wang
Journal:  Thorac Cancer       Date:  2020-09-28       Impact factor: 3.500

9.  Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.

Authors:  Jiajia Chen; Rong Wu; Ying Xuan; Min Jiang; Yuecan Zeng
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

10.  Circ_0001944 Contributes to Glycolysis and Tumor Growth by Upregulating NFAT5 Through Acting as a Decoy for miR-142-5p in Non-Small Cell Lung Cancer.

Authors:  Yawei Dou; Wei Tian; Hongtao Wang; Shanshan Lv
Journal:  Cancer Manag Res       Date:  2021-05-11       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.